Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Treasury Shares (2017 - 2025)

Sonoma Pharmaceuticals has reported Treasury Shares over the past 7 years, most recently at $82000.0 for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $82000.0; the TTM value through Dec 2025 reached $82000.0, changed N/A, while the annual FY2025 figure was $45000.0, N/A changed from the prior year.
  • Treasury Shares for Q4 2025 was $82000.0 at Sonoma Pharmaceuticals, down from $105500.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $833000.0 in Q2 2021 and troughed at $833.0 in Q1 2021.
  • A 3-year average of $171833.3 and a median of $82000.0 in 2025 define the central range for Treasury Shares.
  • On a YoY basis, Treasury Shares climbed as much as 16560.0% in 2021 and fell as far as 50.0% in 2021.
  • Year by year, Treasury Shares stood at $833000.0 in 2021, then crashed by 96.28% to $31000.0 in 2023, then surged by 164.52% to $82000.0 in 2025.
  • Business Quant data shows Treasury Shares for SNOA at $82000.0 in Q4 2025, $105500.0 in Q3 2025, and $105500.0 in Q2 2025.